pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Giapreza
drug
save

angiotensin II acetate

Marketedupdated 2mo ago
by La Jolla Pharmaceutical Company
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying angiotensin II acetate

  • EP1Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastanceactive not recruitingn=30
  • phase2Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)recruitingn=15

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 16, 2029
~3.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (33)

  • Jan 6, 2037method-of-use (U-3262)US 11219662
  • Jan 6, 2037method-of-use (U-3262)US 11219662
  • Jan 6, 2037method-of-use (U-3262)US 11219662
  • Dec 18, 2034method-of-use (U-2338)US 10028995
  • Dec 18, 2034method-of-use (U-2338)US 10028995
  • Dec 18, 2034method-of-use (U-2338)US 10028995
  • Dec 18, 2034method-of-use (U-2679)US 10493124
  • Dec 18, 2034method-of-use (U-2679)US 10493124
  • Dec 18, 2034method-of-use (U-2679)US 10493124
  • Dec 18, 2034method-of-use (U-3211)US 11096983
  • Dec 18, 2034method-of-use (U-3212)US 11096983
  • Dec 18, 2034method-of-use (U-3212)US 11096983
  • Dec 18, 2034method-of-use (U-3514)US 11559559
  • Dec 18, 2034method-of-use (U-3514)US 11559559
  • Dec 18, 2034method-of-use (U-3514)US 11559559
  • Dec 18, 2034method-of-use (U-2218)US 9220745
  • Dec 18, 2034method-of-use (U-2218)US 9220745
  • Dec 18, 2034method-of-use (U-2217)US 9220745
  • Jul 18, 2031method-of-use (U-2221)US 95728565.0y
  • Jul 18, 2031method-of-use (U-2221)US 95728565.0y
  • Nov 20, 2030method-of-use (U-2221)US 95728564.3y
  • Dec 16, 2029method-of-use (U-2581)US 103354513.4y
  • Dec 16, 2029method-of-use (U-2581)US 103354513.4y
  • Dec 16, 2029method-of-use (U-2581)US 103354513.4y
  • Dec 16, 2029method-of-use (U-2680)US 105002473.4y
  • Dec 16, 2029method-of-use (U-2680)US 105002473.4y
  • Dec 16, 2029method-of-use (U-2680)US 105002473.4y
  • Dec 16, 2029method-of-use (U-2739)US 105489433.4y
  • Dec 16, 2029method-of-use (U-2739)US 105489433.4y
  • Dec 16, 2029method-of-use (U-2739)US 105489433.4y
  • Dec 16, 2029method-of-use (U-2231)US 98678633.4y
  • Dec 16, 2029method-of-use (U-2231)US 98678633.4y
  • Dec 16, 2029method-of-use (U-2231)US 98678633.4y

News(0)

no news has mentioned this drug yet

brand
Giapreza
generic
angiotensin II acetate
indication
Hypotension
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 13m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?